As Jaguar announced this past Wednesday, May 13, 2020, Mytesi sales in April 2020 to Cardinal Health have a gross value of $2,753,639. As with all Mytesi gross sales, this figure will be reduced by Medicare, ADAP 340B chargebacks, returns, and wholesale distribution fees based on historical trends to determine net sales.

Company Plans to File Q1 2020 10-Q on May 14, 2020 SAN FRANCISCO, CA / ACCESSWIRE / May 12, 2020 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced that ...

"We are very pleased to see strong Mytesi® (crofelemer) sales growth in 2019 over 2018," Lisa Conte, Jaguar's president and CEO, commented. Under NIAID's suite of preclinical services, NIAID-funded contractors will conduct toxicology testing for a 28-day rat study.

SAN FRANCISCO, CA / ACCESSWIRE / May 20, 2020 / Jaguar Health, Inc. (JAGX) today announced that the company's wholly owned subsidiary, Napo Pharmaceuticals, Inc. ("Napo") is launching a program to educate insurance companies about the benefits of Napo's plant-based Mytesi (crofelemer) prescription drug and negotiate better access to Mytesi for commercially insured patients. A non-opiate antidiarrheal indicated for the symptomatic relief of noninfectious diarrhea in adult patients with HIV/AIDS on antiretroviral therapy, Mytesi is the first and only natural, oral drug approved under U.S. Food and Drug Administration Botanical Guidance.

Company Filed its Annual Report on April 3, 2020 on Form 10-K for the Fiscal Year Ended December 31, 2019 SAN FRANCISCO, CA / ACCESSWIRE / April 3, 2020 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" ...

The discussion is part of Napo's monthly "HIV Community Conversations" series and can be viewed on Napo's Facebook page: facebook.com/napopharma. The upcoming discussion is the seventh event in the HIV Community Conversations series, which brings key advocates and activists in the HIV community together to talk about issues that matter most to people living with and affected by HIV/AIDS.

Shareholder returns likely to be affected by need for companies to be sensitive to magnitude of crisis Continue reading...

NapoCares ™ patient support program provides FDA-approved, plant-based non-opioid Mytesi ® to treat non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy Launch of expanded NapoCares ...

SAN FRANCISCO, CA / ACCESSWIRE / May 26, 2020 / Jaguar Health, Inc.'s (JAGX) head of sustainability Steven King, Ph.D., was interviewed on the Foodie Pharmacology podcast about the pioneering fair-trade tree-to-bottle development of Mytesi® (crofelemer), a non-opioid oral plant-based medicine approved by the U.S. Food and Drug Administration for HIV-related diarrhea. Dr. King, who also oversees ethnobotanical research and intellectual property at Jaguar, spoke with ethnobotanist Dr. Cassandra Quave on May 18 for Foodie Pharmacology, a science podcast for the food curious, the flavor connoisseurs, chefs, science geeks, plant lovers and adventurous taste experimenters out in the world.

SAN FRANCISCO, CA / ACCESSWIRE / May 15, 2020 / Jaguar Health, Inc. (JAGX) (''Jaguar'' or the ''Company'') today announced the voting results from the Annual Meeting of Stockholders of the Company (the "Annual Meeting") that was held on May 15, 2020. Four proposals were submitted to and approved by the stockholders of the Company at the Annual Meeting. The proposals are described in detail in the Company's definitive proxy statement on Schedule 14A relating to the Annual Meeting filed with the SEC on April 13, 2020.

Jaguar has been informed by the FDA's Center for Veterinary Medicine ("CVM") that the CMC technical section, which covers the methods and controls Jaguar has in place for manufacturing, processing, and packaging of Canalevia, has been deemed Complete as part of the Company's application for conditional approval of Canalevia for CID under the Minor Use/Minor Species (MU/MS) section of The Minor Use and Minor Species Animal Health Act of 2004. The MU/MS designation is modeled on the orphan-drug designation for human drug development.

Even the best investor on earth makes unsuccessful investments. But it should be a priority to avoid stomach churning...

Q4 2019 Jaguar Health Inc Earnings Call

"We're very pleased to have executed this transaction," Lisa Conte, Jaguar's president and CEO, stated, "as it supports our strategy of supporting our patient access programs to remove barriers for people living with HIV/AIDS to access Mytesi®, our non-opioid, oral, plant-based drug product, as we continue to work to become a financially sustainable business supported by growth in Mytesi sales for its FDA-approved indication." On May 22, 2020, the Company reduced the exercise price of all Series 1 Warrants and Series 2 Warrants issued as part of the July 2019 financing (collectively, the "Original Warrants") from $1.40 per share to $0.49 per share and from $2.00 per share to $0.49 per share, respectively, and all the warrants to purchase common stock previously issued in private placements by the Company in March through June of 2019 (the "Bridge Warrants") from $2.00 per share to $0.49 per share.

SAN FRANCISCO, CA / ACCESSWIRE / April 16, 2020 / Jaguar Health, Inc. (JAGX) today announced it has entered into an agreement with Atlas Sciences, LLC to develop NP-500, a non-core Jaguar plant-based type II diabetes drug candidate which has successfully completed Phase 1 clinical trials. The deal involves the receipt of $1.5 million by Napo Pharmaceuticals, Inc. (Napo), Jaguar's wholly-owned subsidiary, for sale of NP-500's technology and intellectual property to Atlas Sciences.

Canalevia is the first and only oral plant-based prescription drug candidate for EID in dogs Diarrhea is a common problem among working dogs subjected to intense, long-duration off-leash exercise SAN FRANCISCO, ...

SAN FRANCISCO, CA / ACCESSWIRE / May 13, 2020 / Jaguar Health, Inc. (JAGX) today announced that Jaguar and its wholly owned subsidiary, Napo Pharmaceuticals, Inc., (collectively, the "Company") have jointly entered into an accounts receivable purchase agreement with Oasis Capital, LLC ("Oasis") pursuant to which Oasis has initially agreed to purchase all of the Company's accounts receivable related to the April 2020 sales of the Company's Mytesi® drug product to Cardinal Health, Inc. (the "April 2020 Accounts Receivable"). The April 2020 Accounts Receivable have a gross value of $2,753,639.

SAN FRANCISCO, CA / ACCESSWIRE / February 6, 2020 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company"), today announced that the Company's wholly-owned subsidiary, Napo Pharmaceuticals, ...

SAN FRANCISCO, CA / ACCESSWIRE / February 20, 2020 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company"), today announced that the nonprofit American Botanical Council (ABC) ...

Under the Agreement, Jaguar will immediately receive $0.350 million in connection with the sale of a royalty interest to Iliad entitling Iliad to receive $0.500 million of future royalties on sales of Mytesi® (crofelemer) and certain up-front license fees and milestone payments from licensees and/or distributors. Royalty payments will initiate in six months and will involve minimum monthly payments.